Sofosbuvir and velpatasvir
- Generic Name
- Sofosbuvir and velpatasvir
- Indication
1.用于治疗基因1～6型、混合型及未知型慢性丙型肝炎病毒(HCV) 的成人感染患者。
2.美国FDA批准用于治疗6岁及以上或体重超过17千克的6种基因型（GT-1,-2,-3,-4,-5,-6）的HCV儿童感染者（无肝硬化或轻度肝硬化）。
Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients
- Conditions
- Human Immunodeficiency VirusHepatitis C Virus Infection, Response to Therapy of
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 228
- Registration Number
- NCT03250910
- Locations
- 🇨🇳
National Taiwan University Hospital, Yun-Lin Branch, Douliu, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic
- Conditions
- Hepatitis C, ChronicOpiate DependenceHepatitis C
- Interventions
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Community Research Initiative of New England
- Target Recruit Count
- 11
- Registration Number
- NCT03235154
- Locations
- 🇺🇸
Cambridge Health Alliance Outpatient Addiction Services, Somerville, Massachusetts, United States
Expanding the Pool in Orthotopic Heart Transplantation
- Conditions
- Heart TransplantHepatitis CCardiac Transplant
- Interventions
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Mary E. Keebler, MD
- Target Recruit Count
- 20
- Registration Number
- NCT03222531
- Locations
- 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States
Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1
- Registration Number
- NCT03207399
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Transplanting Hepatitis C Positive Organs
- Conditions
- Hepatitis CAwaiting Organ Transplant
- Interventions
- Other: Monitoring
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 148
- Registration Number
- NCT03086044
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection
- Conditions
- Opioid-use DisorderHepatitis C, Chronic
- Interventions
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Elizabeth Krans, MD
- Target Recruit Count
- 32
- Registration Number
- NCT03057847
- Locations
- 🇺🇸
Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Ala'a Sharara
- Target Recruit Count
- 7
- Registration Number
- NCT03032666
- Locations
- 🇱🇧
American University of Beirut Medical Center, Beirut, Lebanon
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 10
- Registration Number
- NCT02825212
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Surveillance and Treatment of Prisoners With Hepatitis C
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 3692
- Registration Number
- NCT02064049
- Locations
- 🇦🇺
Goulburn Correctional Centre, Goulburn, New South Wales, Australia
🇦🇺Dillwynia Correctional Centre, Windsor, New South Wales, Australia
🇦🇺Outer Metropolitan Multipurpose Correctional Centre, Windsor, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.